PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
Maria Clara Saad Menezes, Farah Raheem, Lida A. Mina, Brenda Ernst, Felipe Batalini
Abstract
Poly-adenosine diphosphate ribose polymerase (PARP) inhibitors (PARPi) are approved for BRCA1/2 carriers with HER2-negative breast cancer in the adjuvant setting with a high risk of recurrence as well as the metastatic setting. However, the indications for PARPi are broader for patients with other cancer types (e.g., prostate and ovarian cancer), involving additional biomarkers (e.g., ATM, PALB2, and CHEK) and genomic instability scores. Herein, we summarize the data on PARPi and breast cancer and discuss their use beyond BRCA carriers.
Topics & Concepts
Breast cancerPALB2MedicinePoly ADP ribose polymeraseOncologyInternal medicinePARP inhibitorProstate cancerCancerMetastatic breast cancerCancer researchOlaparibSynthetic lethalityPolymeraseGermline mutationDNA repairBiologyMutationGeneticsDNAGenePARP inhibition in cancer therapyBRCA gene mutations in cancerDNA Repair Mechanisms